{"id":"NCT03789292","sponsor":"Celltrion","briefTitle":"A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis","officialTitle":"A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P17 With Humira When Co-administered With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-11-26","primaryCompletion":"2019-10-08","completion":"2020-04-24","firstPosted":"2018-12-28","resultsPosted":"2021-11-17","lastUpdate":"2021-11-17"},"enrollment":648,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"CT-P17 SC","otherNames":[]},{"type":"BIOLOGICAL","name":"Humira SC","otherNames":[]}],"arms":[{"label":"CT-P17 Subcutaneous(SC) (adalimumab)","type":"EXPERIMENTAL"},{"label":"Humira SC (adalimumab)","type":"ACTIVE_COMPARATOR"}],"summary":"This is a Phase III Study to Compare Efficacy and Safety of CT-P17 with Humira in Patients With Active Rheumatoid Arthritis","primaryOutcome":{"measure":"American College of Rheumatology(ACR)20 Response Rate at Week 24.","timeFrame":"Week 24","effectByArm":[{"arm":"CT-P17 Subcutaneous(SC) (Adalimumab)","deltaMin":268,"sd":null},{"arm":"EU-approved Humira SC (Adalimumab)","deltaMin":268,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":1,"countries":["Bulgaria"]},"refs":{"pmids":["34142111","33546755"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":324},"commonTop":["Upper respiratory tract infection","Neutropenia","Nasopharyngitis","Urinary tract infection","Injection site reaction"]}}